Skip to main content
. 2023 May 16;63:102719. doi: 10.1016/j.redox.2023.102719

Fig. 7.

Fig. 7

Activity profiles of top GPX4 inhibitors. Structure and activity profile of A) pranlukast sodium hydrate; B) lusutrombopag C) brilanestrant; D) simeprevir E) grazoprevir (MK-5172); F) paritaprevir; G) navitoclax; H) venetoclax; I) VU0661013. Data are normalized to DMSO and presented as mean ± s.d. of n = 3 replicates.